Novo Nordisk shares tumbled Tuesday after the Danish pharmaceutical giant released updated financial guidance that, while improved from previous projections, failed to meet investor expectations. The selloff came despite solid second quarter results and growing momentum for the company's expanding portfolio of obesity treatments.
U.S.-listed shares of Novo Nordisk fell more than 6% at 3 p.m. ET after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year. Investors appeared to focus on the company's cautious forecast rather than its stronger-than-expected operational performance.
